Several oncogenic driver mutations, e.g., epidermal growth factor receptor (EGFR; 15–20% of NSCLCs) and anaplastic lymphoma kinase (ALK; 5% of NSCLCs), have been shown to promote cell transformation and cancer growth and progression [1]. This evidence concerns the gene ALK and cancer.